PMID- 11160437
OWN - NLM
STAT- MEDLINE
DCOM- 20010405
LR  - 20191023
IS  - 1529-2401 (Electronic)
IS  - 0270-6474 (Print)
IS  - 0270-6474 (Linking)
VI  - 21
IP  - 2
DP  - 2001 Jan 15
TI  - Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor 
      are required simultaneously for survival of dopaminergic primary sensory neurons 
      in vivo.
PG  - 581-9
AB  - Null mutations affecting members of the transforming growth factor-beta and 
      neurotrophin families result in overlapping patterns of neuronal cell death. This 
      is particularly striking in the cranial sensory nodose-petrosal ganglion complex 
      (NPG), in which loss of either glial cell line-derived neurotrophic factor 
      (GDNF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), or 
      neurotrophin-4 (NT-4) results in a 30-50% reduction in neuronal survival. It is 
      unknown, however, whether GDNF and any single neurotrophin support survival of 
      the same cells, and if so, whether they are required simultaneously or 
      sequentially during development. To approach these issues we defined survival 
      requirements of nodose and petrosal neurons for GDNF in vitro and in bdnf, gdnf, 
      and bdnf/gdnf null mutant mice, as well as the distribution of GDNF in NPG target 
      tissues. Our analyses focused on the total population of ganglion cells as well 
      as the subset of NPG neurons that are dopaminergic. Neuron losses in bdnf/gdnf 
      double mutants are not additive of the losses in single bdnf or gdnf null 
      mutants, indicating that many cells, including dopaminergic neurons, require both 
      GDNF and BDNF for survival in vivo. Moreover, both factors are required during 
      the same period of development, between embryonic day (E) 15.5 and E17.5. In 
      addition, GDNF, like BDNF is expressed in target tissues at the time of initial 
      target innervation and coincident with GDNF dependence of the innervating 
      neurons. Together, these findings demonstrate that both GDNF and BDNF can act as 
      target-derived trophic factors and are required simultaneously for survival of 
      some primary sensory neurons.
FAU - Erickson, J T
AU  - Erickson JT
AD  - Department of Neurosciences, Case Western Reserve University School of Medicine, 
      Cleveland, Ohio 44106, USA.
FAU - Brosenitsch, T A
AU  - Brosenitsch TA
FAU - Katz, D M
AU  - Katz DM
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Neurosci
JT  - The Journal of neuroscience : the official journal of the Society for 
      Neuroscience
JID - 8102140
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Drosophila Proteins)
RN  - 0 (Gdnf protein, mouse)
RN  - 0 (Gdnf protein, rat)
RN  - 0 (Glial Cell Line-Derived Neurotrophic Factor)
RN  - 0 (Glial Cell Line-Derived Neurotrophic Factor Receptors)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - EC 1.14.16.2 (Tyrosine 3-Monooxygenase)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-ret)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Ret protein, Drosophila)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/genetics/*metabolism/pharmacology
MH  - Carotid Body/physiology
MH  - Cell Count
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Dopamine/*metabolism
MH  - *Drosophila Proteins
MH  - Glial Cell Line-Derived Neurotrophic Factor
MH  - Glial Cell Line-Derived Neurotrophic Factor Receptors
MH  - Immunohistochemistry
MH  - Mice
MH  - Mice, Knockout
MH  - *Nerve Growth Factors
MH  - Nerve Tissue Proteins/genetics/*metabolism/pharmacology
MH  - Neurons, Afferent/cytology/drug effects/*metabolism
MH  - Nodose Ganglion/cytology/drug effects/metabolism
MH  - Organ Specificity
MH  - Plethysmography
MH  - Proto-Oncogene Proteins/metabolism
MH  - Proto-Oncogene Proteins c-ret
MH  - Rats
MH  - Receptor Protein-Tyrosine Kinases/metabolism
MH  - Respiration/genetics
MH  - Tyrosine 3-Monooxygenase/metabolism
PMC - PMC6763821
EDAT- 2001/02/13 11:00
MHDA- 2001/04/06 10:01
PMCR- 2001/07/15
CRDT- 2001/02/13 11:00
PHST- 2001/02/13 11:00 [pubmed]
PHST- 2001/04/06 10:01 [medline]
PHST- 2001/02/13 11:00 [entrez]
PHST- 2001/07/15 00:00 [pmc-release]
AID - 21/2/581 [pii]
AID - 4921 [pii]
AID - 10.1523/JNEUROSCI.21-02-00581.2001 [doi]
PST - ppublish
SO  - J Neurosci. 2001 Jan 15;21(2):581-9. doi: 10.1523/JNEUROSCI.21-02-00581.2001.